A Single Dose Study to Evaluate the Exposure-Response Relationship Between Galunisertib (LY2157299) and QT Interval in Healthy Japanese and Non-Japanese Subjects
Phase of Trial: Phase I
Latest Information Update: 08 Jul 2016
At a glance
- Drugs Galunisertib (Primary)
- Indications Breast cancer; Cancer; Glioblastoma; Glioma; Liver cancer; Myelodysplastic syndromes; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 30 Jun 2016 Status changed from recruiting to completed.
- 05 May 2016 Status changed from not yet recruiting to recruiting.
- 29 Apr 2016 New trial record